Related Experiment Video
Updated: May 6, 2026
11:34
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
2.2K
Daclatasvir: potential role in hepatitis C
1College of Pharmacy, Dongguk University-Seoul, Goyang, Republic of Korea.
Drug Design, Development and Therapy
|November 9, 2013
Summary
Daclatasvir, a novel NS5A inhibitor, shows promise for treating chronic hepatitis C virus (HCV) infection. This review covers its discovery, mechanism, resistance, and potential role in future interferon-free HCV therapies.
Area of Science:
- Hepatology and Viral Gastroenterology
- Pharmacology and Drug Discovery
Background:
- Chronic hepatitis C virus (HCV) infection leads to liver cirrhosis and hepatocellular carcinoma, posing a significant global health burden.
- Current therapies based on interferon-α and ribavirin are evolving towards interferon-sparing or interferon-free strategies.
- New direct-acting and host-targeting antiviral agents are emerging as critical therapeutic advancements.
Purpose of the Study:
- To review preclinical and clinical studies of daclatasvir, a novel NS5A inhibitor for HCV.
- To discuss the discovery, mechanism of action, viral resistance, and host polymorphism of daclatasvir.
- To explore the potential future role of daclatasvir in managing HCV infection.
Main Methods:
- Comprehensive review of published preclinical and clinical proof-of-concept studies on daclatasvir.
- Analysis of daclatasvir's distinct mechanism of action as a direct-acting antiviral agent.
- Examination of studies related to viral resistance and host genetic factors influencing daclatasvir efficacy.
Main Results:
- Daclatasvir, a new class of direct-acting anti-HCV therapeutic, has demonstrated significant promise in clinical trials.
- Its unique mechanism of action offers a new avenue for HCV treatment.
- Understanding viral resistance and host polymorphisms is crucial for optimizing daclatasvir-based regimens.
Conclusions:
- Daclatasvir represents a promising therapeutic option for chronic hepatitis C virus infection.
- Its distinct mechanism and potential for interferon-free regimens highlight its importance in future HCV management.
- Further research into resistance and host factors will refine its clinical application.
Related Concept Videos
01:25Hepatitis
99
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
99
01:28Viral Hepatitis I: Introduction
28
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
28
01:23Cirrhosis I: Introduction
30
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
30
01:14Hepatic Drug Clearance: Role of Transporters
389
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
389
01:16Hepatic Drug Excretion: Influencing Factors
826
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
826
01:24Cirrhosis II: Pathophysiology
49
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
49